AN2 Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDAN2 Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 17% provides fundamental context to the price action. Investors should exercise caution due to high volatility (130% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.71 | -8.75% | BELOW |
| 50 SMA | $4.60 | -6.51% | BELOW |
| 100 SMA | $3.79 | +13.45% | ABOVE |
| 150 SMA | $2.91 | +47.89% | ABOVE |
| 200 SMA | $2.48 | +73.16% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ANTX in an uptrend right now?
ANTX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ANTX overbought or oversold?
ANTX's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.
Is ANTX outperforming the market?
ANTX has a Relative Strength (RS) Rating of 98 out of 99. Yes, ANTX is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is ANTX in its 52-week range?
ANTX is trading at $4.30, which is 62% of its 52-week high ($6.91) and 56% above its 52-week low ($1.00).
How volatile is ANTX?
ANTX has a Beta of 0.51 and 52-week volatility of 130%. It's less volatile than the S&P 500 - generally more stable.